About four years in the making, Monday's reveal of disappointing top-line data from the phase III study testing vosaroxin plus cytarabine in patients with relapsed refractory acute myeloid leukemia (AML) sent shares of Sunesis Pharmaceuticals Inc. tumbling in spectacular fashion.